Generation of a homozygous TIGIT gene knockout (TIGIT−/−) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system
Adoptive cell therapy for solid cancers involves enhancing and reinfusing immune cells to target tumor cells. The advancement of induced pluripotent stem cell technology enables the generation of immune cell products like T and NK cells for ACT. However, the expression of inhibitory receptors, such...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Stem Cell Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S187350612400299X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Adoptive cell therapy for solid cancers involves enhancing and reinfusing immune cells to target tumor cells. The advancement of induced pluripotent stem cell technology enables the generation of immune cell products like T and NK cells for ACT. However, the expression of inhibitory receptors, such as TIGIT, may limit the functionality of these immune effector cells. In this study, we generated a homozygous TIGIT gene knockout iPSC line to potentially prevent inhibitory signaling and exhaustion, thereby creating potent “off-the-shelf” immune cell products for cellular immunotherapy applications. This approach could offer a new frontier in the fight against solid tumors. |
|---|---|
| ISSN: | 1873-5061 |